trimetrexate has been researched along with EHS Tumor in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, WW | 2 |
| Lin, JT | 2 |
| Schweitzer, BI | 1 |
| Bertino, JR | 2 |
| Chang, YM | 1 |
| Schweitzer, B | 1 |
2 other studies available for trimetrexate and EHS Tumor
| Article | Year |
|---|---|
Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Topics: Aminopterin; Animals; Drug Resistance; Folic Acid Antagonists; Leucovorin; Methotrexate; Methylchola | 1991 |
Prediction of antifolate efficacy in a rat sarcoma model.
Topics: Aminopterin; Animals; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Male; Methotrexate; | 1991 |